The early mineralocorticoid effector mechanism, the sodium-proton exchanger, is sensitized in lymphocytes from patients with Cushing's syndrome.
OBJECTIVE
In-vitro binding of aldosterone to mineralocorticoid receptors on human mononuclear leucocytes and its effects on the intracellular sodium and potassium concentrations, the sodium-proton exchanger and cell volume of human mononuclear leucocytes have been described for normals. In the present paper this easily accessible human cell model was studied in Cushing's syndrome to detect abnormalities of the mineralocorticoid effector mechanism.


METHODS
The rate of cell swelling in isotonic sodium propionate reflecting the activity of the sodium-proton exchanger and the stimulatory activity of 1.4 nM aldosterone were determined in a Coulter Channelyzer.


METHODS
Nine female patients with pituitary-dependent (7) and adrenal hypercortisolism (2) were included in the study.


METHODS
Compared with controls from matched normals, the cell volume of human mononuclear leucocytes in a physiological buffer was significantly increased in the patients. The increment of cell size in isotonic sodium propionate was elevated in the presence of 1.4 nM aldosterone only.


RESULTS
These findings are equivalent to an excess stimulation of the sodium-proton exchanger by aldosterone in these patients. Plasma cortisol was inversely correlated with the cell swelling in propionate.


CONCLUSIONS
These data indicate that the early mineralocorticoid effector mechanism in human mononuclear leucocytes from patients with Cushing's syndrome has an increased sensitivity to aldosterone compared with that from normals. This could reflect an adaptation of the cellular electrolyte metabolism to the decreased mineralocorticoid activity balancing the increased glucocorticoid activity. If representative of other cell systems, e.g. renal tubular cells, these findings would identify accompanying electrolyte disorders in these patients not as a side-effect of glucocorticoids, but as a result of an increased sensitivity to endogenous mineralocorticoids.
Wehling
M
M
Medizinische Klinik, University of Munich, Germany.
Käsmayr
J
J
Christ
M
M
Sippell
W
W
Theisen
K
K
Müller
O A
OA
D000293:Adolescent; D000328:Adult; D000450:Aldosterone / Q000494:pharmacology*; D002478:Cells, Cultured; D003480:Cushing Syndrome / Q000097:blood / Q000378:metabolism*; D005260:Female; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000378:metabolism*; D008875:Middle Aged; D011188:Potassium / Q000097:blood; D011422:Propionates / Q000494:pharmacology; D012964:Sodium / Q000097:blood; D000254:Sodium-Potassium-Exchanging ATPase / Q000187:drug effects*
D011422:Propionates; D000450:Aldosterone; D012964:Sodium; C514135:sodium propionate; D000254:Sodium-Potassium-Exchanging ATPase; C029658:propionic acid; D011188:Potassium; D006854:Hydrocortisone